<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33625628</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-6830</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Cellular and molecular neurobiology</Title><ISOAbbreviation>Cell Mol Neurobiol</ISOAbbreviation></Journal><ArticleTitle>Main Role of Antibodies in Demyelination and Axonal Damage in Multiple Sclerosis.</ArticleTitle><Pagination><StartPage>1809</StartPage><EndPage>1827</EndPage><MedlinePgn>1809-1827</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10571-021-01059-6</ELocationID><Abstract><AbstractText>Antibodies and oxidative stress are hallmarks of multiple sclerosis (MS) lesions. We aimed to clarify the relation between them, their role in MS patients and to investigate their specificity, comparing MS with classical neurodegenerative diseases (ND). Brain samples from 14 MS cases, 6 with ND and 9 controls (without neurological diseases). Immunohistochemistry assays were used to detect oxidized lipids (EO6), IgG and IgM, oligodendrocytes (Olig2), axons (NF, neurofilament) and cellular (TUNEL) and axonal damage (APP, amyloid precursor protein). We did not observe EO6 in controls. All samples from MS patients showed EO6 in oligodendrocytes and axons within lesions. We did not detect co-localization between EO6 and antibodies. Neither did we between EO6 and TUNEL or APP. 94.4% of TUNEL-positive cells in normal appearing white matter were also stained for IgG and 75.5% for IgM. IgM, but not IgG, co-localized with APP. EO6 was associated with axonal damage in amyotrophic lateral sclerosis (ALS). We did not observe association between antibodies and cellular or axonal damage in ND patients. MS patients showed a higher number of B cells and plasma cells in the lesions and meninges than controls. The number of B cells and plasma cells was associated with the presence of antibodies and with the activity of the lesions. We observed a main role of B lymphocytes in the development of MS lesions. Antibodies contribute to the oligodendrocyte and axonal damage in MS. Oxidative stress was associated with axonal damage in ALS.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mu&#xf1;oz</LastName><ForeName>Ursula</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0001-6024-4697</Identifier><AffiliationInfo><Affiliation>Facultad de Medicina Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, Spain. ursula.munozmoron@ceu.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sebal</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-3948-5901</Identifier><AffiliationInfo><Affiliation>Facultad de Medicina Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escudero</LastName><ForeName>Esther</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-1960-4560</Identifier><AffiliationInfo><Affiliation>Facultad de Medicina Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esiri</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6829-0962</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tzartos</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7948-034X</Identifier><AffiliationInfo><Affiliation>Hellenic Pasteur Institute, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sloan</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadaba</LastName><ForeName>Mari Cruz</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0003-1560-5312</Identifier><AffiliationInfo><Affiliation>Facultad de Medicina Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, Spain. mariacruz.sadabaargaiz@ceu.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L022656/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>PI14/01620</GrantID><Agency>Universidad San Pablo CEU-Banco Santander</Agency><Country/></Grant><Grant><GrantID>MEMERG-1</GrantID><Agency>The Instituto de Medicina Molecular Aplicada, Universidad San Pablo CEU</Agency><Country/></Grant><Grant><GrantID>USP-BS-PPC16/2012</GrantID><Agency>The Instituto de Medicina Molecular Aplicada, Universidad San Pablo CEU</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Mol Neurobiol</MedlineTA><NlmUniqueID>8200709</NlmUniqueID><ISSNLinking>0272-4340</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="Y">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009836" MajorTopicYN="N">Oligodendroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibodies</Keyword><Keyword MajorTopicYN="N">Autoimmunity</Keyword><Keyword MajorTopicYN="N">Multiple sclerosis</Keyword><Keyword MajorTopicYN="N">Neurodegenerative diseases</Keyword><Keyword MajorTopicYN="N">Oxidative stress</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>24</Day><Hour>12</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33625628</ArticleId><ArticleId IdType="doi">10.1007/s10571-021-01059-6</ArticleId><ArticleId IdType="pii">10.1007/s10571-021-01059-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andersson M, Alvarez-Cerme&#xf1;o J, Bernardi G, Cogato I, Fredman P, Frederiksen J, Fredrikson S, Gallo P, Grimaldi LM, Gr&#xf8;nning M (1994) Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 57:897&#x2013;902. https://doi.org/10.1136/jnnp.57.8.897</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.57.8.897</ArticleId><ArticleId IdType="pubmed">8057110</ArticleId><ArticleId IdType="pmc">1073070</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranzini SE, Jeong MC, Butunoi C, Murray RS, Bernard CC, Oksenberg JR (1999) B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 163:5133&#x2013;5144</Citation><ArticleIdList><ArticleId IdType="pubmed">10528220</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnett MH, Prineas JW (2004) Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 55(4):458&#x2013;468</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20016</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, Witztum JL (2002) Innate and acquired immunity in atherogenesis. Nat Med 8:1218&#x2013;1226. https://doi.org/10.1038/nm1102-1218</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1102-1218</ArticleId><ArticleId IdType="pubmed">12411948</ArticleId></ArticleIdList></Reference><Reference><Citation>Bizzozero OA, DeJesus G, Callahan K, Pastuszyn A (2005) Elevated protein carbonylation in the brain white matter and gray matter of patients with multiple sclerosis. J Neurosci Res 81:687&#x2013;695. https://doi.org/10.1002/jnr.20587</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.20587</ArticleId><ArticleId IdType="pubmed">16007681</ArticleId></ArticleIdList></Reference><Reference><Citation>Breij EC, Brink BP, Veerhuis R, van den Berg C, Vloet R, Yan R, Dijkstra CD, van der Valk P, B&#xf6; L (2008) Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 63:16&#x2013;25. https://doi.org/10.1002/ana.21311</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21311</ArticleId><ArticleId IdType="pubmed">18232012</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Le WD, Xie WJ, Alexianu ME, Engelhardt JI, Sikl&#xf3;s L, Appel SH (1998) Experimental destruction of substantianigra initiated by Parkinson disease immunoglobulins. Arch Neurol 55:1075&#x2013;1080. https://doi.org/10.1001/archneur.55.8.1075</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.55.8.1075</ArticleId><ArticleId IdType="pubmed">9708957</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcione A, Casaza S, Ferretti E, Giunti D, Zappia E, Pistorio A, Gambini C, Mancardi GL, Uccelli A, Pistoia V (2004) Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. ProcNatlAcadSci USA 101:11064&#x2013;11069. https://doi.org/10.1073/pnas.0402455101</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0402455101</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross AH, Manning PT, Keeling RM, Schmidt RE, Misko TP (1998) Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol 88:45&#x2013;56. https://doi.org/10.1016/s0165-5728(98)00078-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0165-5728(98)00078-2</ArticleId><ArticleId IdType="pubmed">9688323</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Sanchez M, Williams K, DeLuca GC, Esiri MM (2006) Protein co-expression with axonal injury in multiple sclerosis plaques. ActaNeuropathol 111:289&#x2013;299. https://doi.org/10.1007/s00401-006-0045-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0045-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta R, McDonough J, Yin X, Peterson J, Chang A, Torres T, Gudz T, Macklin WB, Lewis DA, Fox RJ et al (2006) Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 59:478&#x2013;489. https://doi.org/10.1002/ana.20736</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20736</ArticleId><ArticleId IdType="pubmed">16392116</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Appel SH (1990) IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol 47:1210&#x2013;1216. https://doi.org/10.1001/archneur.1990.00530110068019</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1990.00530110068019</ArticleId><ArticleId IdType="pubmed">2122877</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Sikl&#xf3;s L, K&#xf6;m&#xfc;ves L, Smith RG, Appel SH (1995) Antibodies to calcium channels from ALS patients passively transferred to mice selectively increase intracellular calcium and induce ultrastructural changes in motoneurons. Synapse 20:185&#x2013;199. https://doi.org/10.1002/syn.890200302</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/syn.890200302</ArticleId><ArticleId IdType="pubmed">7570350</ArticleId></ArticleIdList></Reference><Reference><Citation>England JD, Gamboni F, Levinson SR, Finger TE (1990) Changed distribution of sodium channels along demyelinated axons. ProcNatlAcadSci USA 87:6777&#x2013;6780. https://doi.org/10.1073/pnas.87.17.6777</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.87.17.6777</ArticleId></ArticleIdList></Reference><Reference><Citation>Esiri M (1977) Immunoglobulin-containing cells in multiple-sclerosis plaques. Lancet 310:478&#x2013;480. https://doi.org/10.1016/S0140-6736(77)91603-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(77)91603-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393&#x2013;399. https://doi.org/10.1093/brain/120.3.393</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/120.3.393</ArticleId><ArticleId IdType="pubmed">9126051</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J, Mahad D, Bradl M, Van Horssen J, Lassmann H (2012) NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 135:886&#x2013;899. https://doi.org/10.1093/brain/aws012</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws012</ArticleId><ArticleId IdType="pubmed">22366799</ArticleId><ArticleId IdType="pmc">3286337</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer MT, Wimmer I, H&#xf6;ftberger R, Gerlach S, Haider L, Zrzavy T, Hametner S, Mahad D, Binder CJ, Krumbholz M et al (2013) Disease-specific molecular events in cortical multiple sclerosis lesions. Brain 136:1799&#x2013;1815. https://doi.org/10.1093/brain/awt110</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt110</ArticleId><ArticleId IdType="pubmed">23687122</ArticleId><ArticleId IdType="pmc">3673462</ArticleId></ArticleIdList></Reference><Reference><Citation>Gay FW, Drye TJ, Dick GWA, Esiri MM (1997) The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis: identification and characterization of the primary demyelinating lesion. Brain 120:1461&#x2013;1483. https://doi.org/10.1093/brain/120.8.1461</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/120.8.1461</ArticleId><ArticleId IdType="pubmed">9278635</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas J, Bekeredjian-Ding I, Milkova M, Balint B, Schwarz A, Korporal M, Jarius S, Fritz B, Lorenz HM, Wildemann B (2011) B cells undergo unique compartmentalized redistribution in multiple sclerosis. J Autoimmun 37:289&#x2013;299. https://doi.org/10.1016/j.jaut.2011.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2011.08.003</ArticleId><ArticleId IdType="pubmed">21924866</ArticleId></ArticleIdList></Reference><Reference><Citation>Haider L, Fischer MT, Frischer JM, Bauer J, Hoftberger R, Botond G, Esterbauer H, Binder CJ, Witztum JL, Lassmann H (2011) Oxidative damage in multiple sclerosis lesions. Brain 134:1914&#x2013;1924. https://doi.org/10.1093/brain/awr128</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr128</ArticleId><ArticleId IdType="pubmed">21653539</ArticleId><ArticleId IdType="pmc">3122372</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox R, Bar-Or A, Panzara M, Sarkar N, Agarwal S et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676&#x2013;688. https://doi.org/10.1056/nejmoa0706383</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa0706383</ArticleId><ArticleId IdType="pubmed">18272891</ArticleId></ArticleIdList></Reference><Reference><Citation>Ireland SJ, Blazek M, Harp CT, Greenberg B, Frohman EM, Davis LS, Monson NL (2012) Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity. Autoimmunity 45:400&#x2013;414. https://doi.org/10.3109/08916934.2012.665529</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/08916934.2012.665529</ArticleId><ArticleId IdType="pubmed">22432732</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ (2016) Tauopathies as clinicopathological entities. Parkinsonism RelatDisord 22(Suppl 1):S29-33. https://doi.org/10.1016/j.parkreldis.2015.09.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2015.09.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenner P, Dexter DT, Sian J, Schapira AH, Marsden CD (1992) Oxidative stress as a cause of nigral cell death in Parkinson&#x2019;s disease and incidental lewy body disease the royal Kings and Queens Parkinson&#x2019;s disease research group. Ann Neurol 32(Suppl):S82-87. https://doi.org/10.1002/ana.410320714</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410320714</ArticleId><ArticleId IdType="pubmed">1510385</ArticleId></ArticleIdList></Reference><Reference><Citation>Kankaanp&#xe4;&#xe4; J, Turunen SP, Moilanen V, H&#xf6;rkk&#xf6; S, Remes AM (2009) Cerebrospinal fluid antibodies to oxidized LDL are increased in Alzheimer&#x2019;s disease. Neurobiol Dis 33:467&#x2013;472. https://doi.org/10.1016/j.nbd.2008.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2008.12.001</ArticleId><ArticleId IdType="pubmed">19130885</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC (2011) Amyotrophic lateral sclerosis. Lancet 377:942&#x2013;955. https://doi.org/10.1016/s0140-6736(10)61156-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Kook MC, Shin YK, Park SH, Song HG (2004) Evaluation of antigen retrieval buffer systems. J MolHistol 35:409&#x2013;416. https://doi.org/10.1023/B:HIJO.0000039854.17808.e0</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:HIJO.0000039854.17808.e0</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Smith RG, Delbono O, Nyormoi O, Schneider T, Nastainczyk W, Hofmann F, Stefani E, Appel SH (1994) Amyotrophic lateral sclerosis patient antibodies label Ca2+ channel alpha 1 subunit. Ann Neurol 35:164&#x2013;171. https://doi.org/10.1002/ana.410350207</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410350207</ArticleId><ArticleId IdType="pubmed">8109897</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu JS, Zhao ML, Brosnan CF, Lee SC (2001) Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 158:2057&#x2013;2066. https://doi.org/10.1016/s0002-9440(10)64677-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0002-9440(10)64677-9</ArticleId><ArticleId IdType="pubmed">11395383</ArticleId><ArticleId IdType="pmc">1891989</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovato L, Willis SN, Rodig SJ, Caron T, Almendinger SE, Howell OW, Reynolds R, O&#x2019;Connor KC, Hafler DA (2011) Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain 134:534&#x2013;541. https://doi.org/10.1093/brain/awq350</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq350</ArticleId><ArticleId IdType="pubmed">21216828</ArticleId><ArticleId IdType="pmc">3030766</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H (1996) Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 6:259&#x2013;274. https://doi.org/10.1111/j.1750-3639.1996.tb00854.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.1996.tb00854.x</ArticleId><ArticleId IdType="pubmed">8864283</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucchinetti CF, Br&#xfc;ck W, Parisi JE, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogenity of multiple sclerosis lesions: implication for the pathogenesis of demyelination. Ann Neurol 47:707&#x2013;717. https://doi.org/10.1002/1531-8249(200006)47:6%3C707::aid-ana3%3e3.0.CO;2-q</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(200006)47:6%3C707::aid-ana3&gt;3.0.CO;2-q</ArticleId><ArticleId IdType="pubmed">10852536</ArticleId></ArticleIdList></Reference><Reference><Citation>Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R, Aloisi F (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130:1089&#x2013;1104. https://doi.org/10.1093/brain/awm038</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awm038</ArticleId><ArticleId IdType="pubmed">17438020</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahad D, Ziabreva I, Lassmann H, Turnbull D (2008) Mitochondrial defects in acute multiple sclerosis lesions. Brain 131:1722&#x2013;1735. https://doi.org/10.1093/brain/awn105</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn105</ArticleId><ArticleId IdType="pubmed">18515320</ArticleId><ArticleId IdType="pmc">2442422</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahad DJ, Ziabreva I, Campbell G, Lax N, White K, Hanson PS, Lassmann H, Turnbull DM (2009) Mitochondrial changes within axons in multiple sclerosis. Brain 132:1161&#x2013;1174. https://doi.org/10.1093/brain/awp046</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp046</ArticleId><ArticleId IdType="pubmed">19293237</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez A, Carmona M, Portero-Otin M, Naud&#xed; A, Pamplona R, Ferrer I (2008) Type-dependent oxidative damage in frontotemporal lobar degeneration: cortical astrocytes are targets of oxidative damage. J NeuropatholExpNeurol 67:1122&#x2013;1136. https://doi.org/10.1097/NEN.0b013e31818e06f3</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31818e06f3</ArticleId></ArticleIdList></Reference><Reference><Citation>Masjuan J, Alvarez-Cerme&#xf1;o JC, Garc&#xed;a-Barrag&#xe1;n N, D&#xed;az-S&#xe1;nchez M, Espi&#xf1;o M, S&#xe1;daba MC, Gonz&#xe1;lez-Porqu&#xe9; P, Mart&#xed;nez San Mill&#xe1;n J, Villar LM (2006) Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology 66:576&#x2013;578. https://doi.org/10.1212/01.wnl.0000198253.35119.83</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000198253.35119.83</ArticleId><ArticleId IdType="pubmed">16505315</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG, Kawamata T, Yamada T, Akiyama H (1991) Reactions of the immune system in chronic degenerative neurological diseases. Can J NeurolSci 18:376&#x2013;379. https://doi.org/10.1017/S0317167100032479</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0317167100032479</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson&#x2019;s disease. Annu Rev Neurosci 28:57&#x2013;87. https://doi.org/10.1146/annurev.neuro.28.061604.135718</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.28.061604.135718</ArticleId><ArticleId IdType="pubmed">16022590</ArticleId></ArticleIdList></Reference><Reference><Citation>Obermeier B, Lovato L, Mentele R, Br&#xfc;ck W, Forne I, Imhof A, Lottspeich F, Turk KW, Willis SN, Wekerle H et al (2011) Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin. J Neuroimmunol 233:245&#x2013;248</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2011.01.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, Cross AH (2010) Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 67:707&#x2013;714. https://doi.org/10.1001/archneurol.2010.99</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.99</ArticleId><ArticleId IdType="pubmed">20558389</ArticleId><ArticleId IdType="pmc">2918395</ArticleId></ArticleIdList></Reference><Reference><Citation>Polman CH, O&#x2019;Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899&#x2013;910. https://doi.org/10.1056/nejmoa044397</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa044397</ArticleId><ArticleId IdType="pubmed">16510744</ArticleId></ArticleIdList></Reference><Reference><Citation>Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227&#x2013;231. https://doi.org/10.1002/ana.410130302</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410130302</ArticleId><ArticleId IdType="pubmed">6847134</ArticleId></ArticleIdList></Reference><Reference><Citation>Prineas JW (1979) Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science 203:1123&#x2013;1125. https://doi.org/10.1126/science.424741</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.424741</ArticleId><ArticleId IdType="pubmed">424741</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O&#x2019;Regan JP, Deng HX (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59&#x2013;62. https://doi.org/10.1038/362059a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14:164&#x2013;174. https://doi.org/10.1111/j.1750-3639.2004.tb00049.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2004.tb00049.x</ArticleId><ArticleId IdType="pubmed">15193029</ArticleId></ArticleIdList></Reference><Reference><Citation>Stadelmann C, Wegner C, Br&#xfc;ck W (2011) Inflammation, demyelination and degeneration - recent insights from MS pathology. BiochimBiophysActa 1812:275&#x2013;282. https://doi.org/10.1016/j.bbadis.2010.07.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2010.07.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H (1998) Multiple sclerosis: in situ evidence for antibody- and complement- mediated demyelination. Ann Neurol 43:465&#x2013;471. https://doi.org/10.1002/ana.410430409</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410430409</ArticleId><ArticleId IdType="pubmed">9546327</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;daba MC, Gonz&#xe1;lez Porqu&#xe9; P, Masjuan J, Alvarez-Cerme&#xf1;o JC, Bootello A, Villar LM (2004) An ultrasensitive method for the detection of oligoclonalIgG bands. J Immunol Methods 284:41&#x2013;145. https://doi.org/10.1016/j.jim.2003.09.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2003.09.018</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;daba MC, Mart&#xed;n-Estal I, Puche JE, Castilla-Cort&#xe1;zar I (2016) Insulin-like growth factor 1 (IGF-1) therapy: mitochondrial dysfunction and diseases. BiochimBiophysActa 1862:1267&#x2013;1278. https://doi.org/10.1016/j.bbadis.2016.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2016.03.010</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;daba MC, Tzartos J, Pa&#xed;no C, Garc&#xed;a-Villanueva M, Alvarez-Cerme&#xf1;o JC, Villar LM, Esiri MM (2012) Axonal and oligodendrocyte-localized IgM and IgG deposits in MS lesions. J Neuroimmunol 247:86&#x2013;94. https://doi.org/10.1016/j.jneuroim.2012.03.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2012.03.020</ArticleId><ArticleId IdType="pubmed">22531276</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsimikas S, Brilakis ES, Lennon RJ, Miller ER, Witztum JL, McConnell JP, Kornman KS, Berger PB (2007) Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res 48:425&#x2013;433. https://doi.org/10.1194/jlr.m600361-jlr200</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.m600361-jlr200</ArticleId><ArticleId IdType="pubmed">17093289</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L (2008) Interleukin-17 production in central nervous system-infiltrating T Cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172:146&#x2013;155. https://doi.org/10.2353/ajpath.2008.070690</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2008.070690</ArticleId><ArticleId IdType="pubmed">18156204</ArticleId><ArticleId IdType="pmc">2189615</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar L, Garc&#xed;a-Barrag&#xe1;n N, Espi&#xf1;o M, Rold&#xe1;n E, S&#xe1;daba M, G&#xf3;mez-Rial J, Gonz&#xe1;lez-Porqu&#xe9; P, Alvarez-Cerme&#xf1;o J (2008) Influence of oligoclonalIgM specificity in multiple sclerosis disease course. MultScler 14:183&#x2013;187. https://doi.org/10.1177/1352458507082046</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458507082046</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar LM, Garc&#xed;a-S&#xe1;nchez MI, Costa-Frossard L, Espi&#xf1;o M, Rold&#xe1;n E, P&#xe1;ramo D, Lucas M, Izquierdo G, &#xc1;lvarez-Cerme&#xf1;o JC (2012) Immunological markers of optimal response to natalizumab in multiple sclerosis. Arch Neurol 69:191&#x2013;197</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.971</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar LM, Masjuan J, Gonz&#xe1;lez-Porqu&#xe9; P, Plaza J, S&#xe1;daba MC, Rold&#xe1;n E, Bootello A, Alvarez-Cerme&#xf1;o JC (2002a) IntrathecalIgM synthesis in neurologic diseases: relationship with disability in MS. Neurology 58:824&#x2013;826. https://doi.org/10.1212/wnl.58.5.824</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.58.5.824</ArticleId><ArticleId IdType="pubmed">11889253</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar LM, Masjuan J, Gonz&#xe1;lez-Porqu&#xe9; P, Plaza J, S&#xe1;daba MC, Rold&#xe1;n E, Bootello A, Alvarez-Cerme&#xf1;o JC (2002b) IntrathecalIgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 59:555&#x2013;559. https://doi.org/10.1212/wnl.59.4.555</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.59.4.555</ArticleId><ArticleId IdType="pubmed">12196648</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar LM, Masjuan J, Gonz&#xe1;lez-Porqu&#xe9; P, Plaza J, S&#xe1;daba MC, Rold&#xe1;n E, Bootello A, Alvarez-Cerme&#xf1;o JC (2003) IntrathecalIgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 53:222&#x2013;226. https://doi.org/10.1002/ana.10441</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10441</ArticleId><ArticleId IdType="pubmed">12557289</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar LM, Masjuan J, S&#xe1;daba MC, Gonz&#xe1;lez-Porqu&#xe9; P, Plaza J, Bootello A, Alvarez-Cerme&#xf1;o JC (2005a) Early differential diagnosis of multiple sclerosis using a new oligoclonal band test. Arch Neurol 62:574&#x2013;577. https://doi.org/10.1001/archneur.62.4.574</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.62.4.574</ArticleId><ArticleId IdType="pubmed">15824255</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar LM, S&#xe1;daba MC, Rold&#xe1;n E, Masjuan J, Gonz&#xe1;lez-Porqu&#xe9; P, Villarrubia N, Espi&#xf1;o M, Garc&#xed;a-Trujillo JA, Bootello A, Alvarez-Cerme&#xf1;o JC (2005b) Intrathecal synthesis of oligoclonalIgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 115:187&#x2013;194. https://doi.org/10.1172/jci22833</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci22833</ArticleId><ArticleId IdType="pubmed">15630459</ArticleId><ArticleId IdType="pmc">539201</ArticleId></ArticleIdList></Reference><Reference><Citation>Vladimirova O, O&#x2019;Connor J, Cahill A, Alder H, Butunoi C, Kalman B (1998) Oxidative damage to DNA in plaques of MS brains. MultScler (Houndmills, Basingstoke, England) 4:413&#x2013;418. https://doi.org/10.1177/135245859800400503</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/135245859800400503</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Z, Li X, Liu Q, Cheng Y (2018) Oxidative stress in Parkinson&#x2019;s disease: a systematic review and meta-analysis. Front MolNeurosci 11:236. https://doi.org/10.3389/fnmol.2018.00236</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00236</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Da RR, Hilgenberg LG, Tourtellotte WW, Sobel RA, Smith MA, Olek M, Nagra R, Sudhir G, van den Noort S et al (2005) Clonal expansion of IgA-positive plasma cells and axon-reactive antibodies in MS lesions. J Neuroimmunol 167:120&#x2013;130. https://doi.org/10.1016/j.jneuroim.2005.05.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2005.05.006</ArticleId><ArticleId IdType="pubmed">16099056</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>